A 70-year-old womanwith small-cell lung carcinoma (c-T4N2M0) was treated by six courses of combination chemotherapy (carboplatin and etoposide). After two weeks, she complained of a sense of darkness and night blindness. A Western blot analysis showedthat the patient's serum bound with the recombinant 23-kDa retinal cancer-associated retinopathy (CAR) antigen at 1 : 1,000 dilution. Her visual acuity becameso poor that she could only recognise a hand motion at 50 cm despite treatment with corticosteroids and combination chemotherapy. The patient was diagnosed as having a rare type of CARbecause CARis usually found before the diagnosis of primary cancer. (Internal Medicine 38: 597-601, 1999) 
Introduction
Cancer-associated retinopathy (CAR), which was first reported by Sawyer et al (1) in 1976, is one of the paraneoplastic syndromeswhich are a remote effect of systemic cancer. CAR is associated with epithelial neoplasm, mostly small-cell lung carcinoma and is characterized by the degeneration of retinal photoreceptors (2-1 1). A photoreceptor protein, recoverin, has been recognized as the autoantigen of this disorder (12) (13) (14) (15) (16) (17) . It has been reported that CARis usually found before the diagnosis of primary cancer, but there have been some reports that this disorder occurred during the treatment of malignant diseases (9, 18, 19) . This report describes a 70-year-old woman with small-cell lung carcinoma who had rapidly progressive visual loss in both eyes during a period of one month.
Case Report
A 70-year-old smoking womanhad complete response of small-cell lung carcinoma (c-T4N2M0) for eleven months with five courses of combination chemotherapy consisting of carboplatin (400 mg/m2 for one day) and etoposide (100 mg/ m2for three days). A roentgenogram of the chest revealed a tumor in the left middle lung field and a relapse of the hilar and mediastinal lymphadenopathy ( Fig. 1) flammatory cells in the anterior chamberand intraocular pressures werenormal. Fundusexaminationshoweda mild narrowing of the retinal blood vessels and slight pallor of both optic disks (Fig. 3 ). Indocyanine green angiography revealed a patchily stained area and narrowed arteries in both eyes (Fig.  4) . Electroretinogram (ERG) was non-recordable. A computed tomogram (CT) and magnetic resonance image (MRI) of the brain and orbit showed no abnormal findings. Laboratory findings, including serum titers for herpes simplex virus, varicellazoster virus and cytomegalovirus, were normal. Over the subsequent two weeks, her vision continued to deteriorate in both eyes. Color vision was severely reduced. A neuro-ophthalmologic examination revealed the visual acuity in the right eye to be 0.05 and in the left eye to be a hand motion at 50 cm, with no change in the ERG.A progressive narrowing of the retinal arteries was found on fundus examination and indocyanine green angiography. A Western blot analysis showed that the patient's serum bound with the recombinant 23-kDa retinal CARantigen at 1 : 1 ,000 dilution (Fig.  5) . On the basis of her clinical signs and neuro-ophthalmologic examination findings, CARwas diagnosed. The patient was given 1,000 mg of methylprednisolone intravenously for three days and started on 40 mg prednisolone per day, which was tapered to 5 mg per week. Plasmapheresis has not been done. She had a temporary improvement of vision for one month, but her vision in both eyes deteriorated due to the advance of the cancer. Although she has been treated with combination chemotherapy (carboplatin and etoposide), her visual acuity in both eyes became to be a hand motion at 50
cm.
Discussion
Disorders of the retina, which often lead to the loss of vision and may result as a remote effect of cancer, have been termed visual paraneoplastic syndrome or CAR.In this syndrome, the nervous system is not invaded by primary or metastatic lesions. Although a variety of cancers can be involved, including endometrial cancer ( 1 8-20) , cancer of the cervix uteri (3) and cutaneous malignant melanoma (21, 22) , CARis most frequently associated with small-cell lung carcinoma (2-1 1 , 23 ). The incidence of CARin each patient with various types of cancer is not clear because this disease has not been looked for in most reported oncological series (23) . The clinical triad of CARwas photosensitivity, ring scotomatous visual loss and attenuated retinal arteriole caliber (24) . A high frequency of night blindness and color loss has been reported in this disease (7) . However, it has been most frequently reported that the initial complaint in patients with CARis visual loss. Slit-lamp examination showed inflammatory cells in the anterior chamber or the vitreous body (7, 8, 10) , and visual field examination showed central scotoma, ring scotoma or overall moderate to severe depression. Fundus examination showednon-specific pigment mottling in the posterior pole and vascular at- tenuation with variable sheathing (23) . In addition, it has been reported that optic discs in CARpatients show mild pallor (7, 1 1, 24) . With regard to the optic disc pallor, chemotherapeutic agent-induced optic neuropathy should be considered in the differential diagnosis in the case which has the occurrence of visual loss during chemotherapy, if the presence of CARantigen is not detected. Although the biologic mechanisms of paraneoplastic degenerative retinopathy have not been fully defined, the presence of specific antibodies in patients with CARsuggest autoimmunity as a contributing factor (2, 25). Thirkill et al (4) reported on the isolation of an autoantibody which reacts strongly the 23-kDa retinal protein, recoverin. This protein is a member of the E-F hand family of calcium-binding proteins involved in the transduction of light by vertebrate photoreceptors and is also identified as an autoantigen in CAR (12, 13) . It has been reported that this photoreceptor-specific protein is expressed by the tumor in CARpatients (16) and by a human lung cancer cell line (MN-1112), which was established from tumors of small-cell lung carcinoma patients with CAR (17, 26) . In addition, expression of recoverin was not found in patients with diabetic retinopathy, age-related macular degeneration and in small-cell lung carcinoma patients without CAR (7, 17) . On the other hand, Adamuset al reported serum antibodies to a 46 kDa protein in CARpatients with various types of cancer and that protein sequence analysis of the peptides from the protein revealed a high homology with human enolase, an important glycolytic enzyme (27 paraneoplastic neuropathy other than CAR.In patients with paraneoplastic sensory neuropathy (28) or paraneoplastic cerebellar degeneration (29) , a polyclonal complement-fixing immunoglobulin G (IgG) antibody (anti-Hu) or anti-Purkinje cell antibodies are found in the serum and cerebrospinal fluid.
Wedid not evaluate those antibodies because our patient had no paresthesia, dysesthesia or cerebellar ataxia. CARis generally found before diagnosis of the underlying primary cancer (2-8, 10, ll) . This remote effect of cancer on the eye should be recognized as a presenting sign of previously undiagnosed malignant disease. There are some reports stating that CARhas developed in patients undergoing treatment for malignant disease including small-cell lung carcinoma (9, 18, 19) . In the present case, there was an ll-month interval from the diagnosis of lung cancer to the onset of CAR.It has been reported that the interval is 9 to 21 months (9, 18, 19) . In addition, CARwas accompanied by progress of malignant diseases in two of three cases (18, 19) , as in the present case.
Although the presence of CARis not predictive of advanced or aggressive malignancy (30) , the onset of this syndrome during the treatment of malignancy maybe related to the advance of malignant diseases. The treatment for CARis immunosuppression with corticosteroids. It has been reported that CARpatients attain a temporary improvement in vision following the administration of prednisolone (5, ll, 24) . But the optimal dose of prednisolone dose is not known. Asystemic response of the malignant diseases to chemotherapyor radiation has not correlated with improvement in visual function (5, 30) . In the present case, administration of prednisolone induced a temporary improvement of her visual impairment, but chemotherapy did not. Plasmapheresiswasreported to have reduced the autoantibody liters, but did not benefit the patient' s declining vision, because of irreversible cell damage (4). CARhas been mainly reported by ophthalmologists because these patients have visual loss before the underlying malignancy is diagnosed. However, in some patients, CARappeared during treatment for lung cancer as in the present case. It is important that in the case of visual loss, not only brain metastasis from primary cancer or drug-induced retinopathy but also CAR is considered.
